Rituximab goes off patent shortly and will soon be very much cheaper both for those with CLL and those with arthritis
..........................................
Intas launches Mabtas, a biosimilar version of Rituximab
Thursday, May 02, 2013, 12:15 Hrs [IST]
Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukaemia (CLL) and Rheumatoid Arthritis apart from Non-Hodgkin's Lymphoma (NHL) in India. With a view to make NHL treatment cost-effective, Mabtas is manufactured in the state of the art, Asia’s only EU GMP facility of Intas Biopharmaceuticals, Ahmedabad.
With the launch of this product, Intas now is the only company to have indigenously developed six biosimilars in the domestic market. The company is India's first and only biopharmaceutical companies to receive European Union - Good Manufacturing Practice (EU-GMP) certification for its microbial manufacturing facility and only company having product under-registration with EMA. Intas Biopharmaceuticals is already a leading manufacturer of Erythropoietin, G-CSF and peg G-CSF for India and have introduced world’s first biosimilar peg G-CSF. Mabtas marks the first monoclonal antibody (mAb) launch from Intas.
End
Written by
Kwenda
To view profiles and participate in discussions please or .
Good competition for Dr. Reddy's Reditux, a Rituxan biosimilar used in India since 2007...
Samsung Electronics and Teva Pharmaceutical both bailed out on biosimilar versions of rituximab (MabThera/Rituxan) last year amid uncertainty in regulation of copycat biologics in the U.S. and expensive development requirements that reduce the financial rewards of the drugs. Yet the $7 billion seller Roche, could find competition from others, as both Novartis's Sandoz unit and Boehringer Ingelheim have had Rituxan in their biosimilar plans.
Question is...who is going to test these new products...???
Came across this list ... interesting that Intas isn't on it....
Rituxan / MabThera (rituximab)
Drug developers:
Amgen: Biosimilar in active development
BioXpress: Biosimilar in active development
Boehringer Ingelheim: BI695500 in Phase III development in U.S., EU, Brazil, Guatemala, Russia, Norway, Ukraine, Argentina, Peru, New Zealand. U.S. study recruiting participants as of April 17, according to ClinicalTrials.gov (NCT01682512)
Celltrion and Hospira: Conducting Phase I trial in South Korea of CT-P10 for RA and another Phase I trial for lymphoma.
Dr. Reddy’s Laboratory: Reditux® marketed in Bolivia, Chile, India, and Peru
iBio: Announces October 5, 2011, that it produces rituximab in nontransgenic green plants. More recent announcements, however, focus on the company’s technologies for developing biosimilar and proprietary drugs. On April 26, 2012, announces results of ongoing tests showing that its immunomodulator molecule lichenase (LicKM) enhances vaccine antigens when produced as fusions to LicKM. iBio said it will offer commercial collaborations and product licenses to the immunomodulator, dubbed iBioModulator™, which last month was awarded U.S. Patent No. 8,404,252. The iBioModulator has been shown in animal models to increase the strength and extend the duration of immune response to a vaccine antigen.
Merck: MK8808 in Phase I development for EU, with trial in Belarus
Pfizer: PF-05280586 set this year to complete a Phase II trial launched March 2012 comparing the biosimilar to Rituxan/MabThera. “This year, we expect data,” Mikael Dolsten, president of Pfizer’s Worldwide Research & Development unit, said on the Q4 2012 earnings conference call January 29.
Probiomed: Kikuzubam® marketed in Bolivia, Chile, Mexico, and Peru
Roche: CEO Severin Schwan was quoted in March as pushing back his company’s anticipated launch of a rituximab biosimilar beyond the 2016 date he had earlier cited in The Wall Street Journal, until the end of this decade.
Sandoz: GP2013 in Phase I/II trial for rheumatoid arthritis and non-Hodgkin’s lymphoma, and a Phase III trial for advanced folicular lymphoma. As of last year, the biosimilar was in Phase II trials in Argentina, Austria, Brazil, France, Germany, India, Italy, Spain, and Turkey.
Stada Arzneimittel: Joined with Gedeon Richter in announcing plans August 2011 to collaborate on biosimilars for rituximab and trastuzumab. Stada receives nonexclusive rights to sell Richter-produced rituximab in Europe and the Commonwealth of Independent States, excluding Russia. In addition to an undisclosed payment to Richter, Stada also agrees to pay Richter based on progress of the development of rituximab to a “low double-digit million Euros”
Recently discontinued efforts:
Teva and Lonza: End planned 544-patient, Phase III clinical trial of TLO11, saying they wanted input from regulators on designing the trial program (October 2012). On April 5, Lonza issues statement denying news reports that it will end its biosimilar joint venture with Teva
Samsung Biologics: Venture between Samsung and Quintiles halts development of SAIT101, in October 2012, reportedly due to uncertainty over biosimilar regulation in the U.S.
Nature and indication: Chimeric mouse-human monoclonal antibody, for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Farewell
LLS Ciitizen USA Study Shows Most Blood Cancer Patients Benefit from an Additional (3rd) COVID-19 Vaccine Dose 
FLAIR Trial - ErnieUK Dehydration in Round 4 FCR (and home made soup)
NICE Recommends Acalabrutinib for treating CLL for certain groups
